According to Merck, launches in other European countries are expected to take place in the coming months, once individual marketing authorizations are granted.
Bioequivalent to the existing Glucophage tablets, the new powder formulation is packaged in individual sachets of 500mg, 850mg and 1,000mg.
Roberto Gradnik, executive vice president of commercial Europe at Merck Serono, said: “Adherence to therapy is increasingly being recognized by physicians as a key condition to achieve glycemic control for patients with diabetes. We are pleased to provide this innovative powder formulation of Glucophage to patients seeking a convenient alternative to tablets which may facilitate their adherence to treatment.”